MOSAIC: A model to assess the cost-effectiveness of remdesivir for admitted COVID-19 patients in South Africa

<table><tr><td>MODEL STRATEGIES</td></tr><tr><td>This model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death</td></tr><tr><td>Four competing strategies are modelled:</td></tr><tr><td>1. The "status quo" summarizes costs and outcomes for patients assuming no dexamethasone or remdesivir</td></tr><tr><td>2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming dexamethasone at 6mg/day</td></tr><tr><td>3. The "remdesivir" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day</td></tr><tr><td>4. The "remdesivr plus dexamethasone" comparator summarizes costs and outcomes for patients assuming remdesivir at 100mg/day plus dexamethasone at 6mg/day</td></tr><tr><td>MODEL OUTCOMES</td></tr><tr><td>Cost: mean cost (general ward, ICU, dexamethasone and remdesivir as appropriate) per admitted patient from the health care provider's perspective</td></tr><tr><td>Health outcomes: mean DALYs and deaths per admitted patient </td></tr><tr><td>Other outcomes: mean ICU days and inpatient days per admitted patient</td></tr><tr><td>Budget impact: mean costs (or savings) associated with intervention implementation</td></tr></table>